X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs DISHMAN PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD DISHMAN PHARMA ORCHID PHARMA LTD/
DISHMAN PHARMA
 
P/E (TTM) x -0.2 25.1 - View Chart
P/BV x 0.2 3.3 4.7% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ORCHID PHARMA LTD   DISHMAN PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
DISHMAN PHARMA
Mar-16
ORCHID PHARMA LTD/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs194374 51.8%   
Low Rs35129 27.2%   
Sales per share (Unadj.) Rs276.5197.8 139.8%  
Earnings per share (Unadj.) Rs-79.221.2 -373.5%  
Cash flow per share (Unadj.) Rs-43.534.7 -125.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs53.9179.9 30.0%  
Shares outstanding (eoy) m70.4580.69 87.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.41.3 32.6%   
Avg P/E ratio x-1.411.9 -12.2%  
P/CF ratio (eoy) x-2.67.2 -36.4%  
Price / Book Value ratio x2.11.4 151.8%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m8,06720,306 39.7%   
No. of employees `0002.80.8 337.8%   
Total wages/salary Rs m2,5275,355 47.2%   
Avg. sales/employee Rs Th6,956.119,252.7 36.1%   
Avg. wages/employee Rs Th902.56,459.5 14.0%   
Avg. net profit/employee Rs Th-1,993.02,064.1 -96.6%   
INCOME DATA
Net Sales Rs m19,47715,961 122.0%  
Other income Rs m407265 153.4%   
Total revenues Rs m19,88416,226 122.5%   
Gross profit Rs m1,1034,103 26.9%  
Depreciation Rs m2,5191,091 231.0%   
Interest Rs m5,227944 553.5%   
Profit before tax Rs m-6,2362,334 -267.2%   
Minority Interest Rs m200-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125624 -20.1%   
Profit after tax Rs m-5,5801,711 -326.1%  
Gross profit margin %5.725.7 22.0%  
Effective tax rate %2.026.7 7.5%   
Net profit margin %-28.710.7 -267.2%  
BALANCE SHEET DATA
Current assets Rs m11,01411,018 100.0%   
Current liabilities Rs m32,0609,517 336.9%   
Net working cap to sales %-108.19.4 -1,149.1%  
Current ratio x0.31.2 29.7%  
Inventory Days Days95110 85.9%  
Debtors Days Days3435 96.3%  
Net fixed assets Rs m29,44016,304 180.6%   
Share capital Rs m705161 436.5%   
"Free" reserves Rs m2,04312,907 15.8%   
Net worth Rs m3,80014,516 26.2%   
Long term debt Rs m9,0184,189 215.3%   
Total assets Rs m46,51029,805 156.0%  
Interest coverage x-0.23.5 -5.6%   
Debt to equity ratio x2.40.3 822.3%  
Sales to assets ratio x0.40.5 78.2%   
Return on assets %-0.88.9 -8.5%  
Return on equity %-146.911.8 -1,245.8%  
Return on capital %-3.717.5 -21.3%  
Exports to sales %37.924.8 152.8%   
Imports to sales %22.63.7 605.5%   
Exports (fob) Rs m7,3783,956 186.5%   
Imports (cif) Rs m4,406596 738.9%   
Fx inflow Rs m7,5134,952 151.7%   
Fx outflow Rs m5,649697 810.7%   
Net fx Rs m1,8654,255 43.8%   
CASH FLOW
From Operations Rs m1,6822,786 60.4%  
From Investments Rs m-9,860-1,529 644.9%  
From Financial Activity Rs m6,644-941 -706.0%  
Net Cashflow Rs m-1,535316 -485.1%  

Share Holding

Indian Promoters % 32.3 61.4 52.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 3.7 124.3%  
FIIs % 3.3 12.7 26.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 22.1 250.2%  
Shareholders   84,811 46,261 183.3%  
Pledged promoter(s) holding % 54.9 35.8 153.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   CIPLA  PFIZER  ALKEM LABORATORIES  SUN PHARMA  SANOFI INDIA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Sep 19, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS